April 21, 2024
U.S. Urea Cycle Disorders Treatment Market

The U.S Urea Cycle Disorders Treatment Market Poised To Benefit From Several Factors In The Forecast Period

The US urea cycle disorders treatment market is poised to exhibit a steady growth by 2030, driven by rising awareness about genetic disorders and availability of better treatment options. The market offers treatment options for disorders pertaining to six enzymes of the urea cycle which help remove ammonia from the body. The inability to remove excessive ammonia can potentially damage the brain and other vital organs if left untreated.

Key players operating in the US urea cycle disorders treatment market are Kawasumi Laboratories Inc., Blood Purification Technologies Inc., AWAK Technologies Pte. Ltd, Triomed AB, Asahi Kasei Medical Corporation, US Kidney Research Corporation, Merit Medical Systems, NIPRO Medical Corporation, Fresenius SE & Co. KGaA.

The urea cycle disorders treatment landscape offers products and services for screening, diagnosing and managing urea cycle disorders. Screening tests such as newborn screening help in early detection while advances in genetic testing facilitate confirmatory diagnosis. Treatment involves dietary protein restriction along with medication and supplements to prevent buildup of toxic ammonia levels. Certain patients may need emergency treatment procedures such as hemodialysis or liver transplantation in critical conditions. The growing recognition of benefits of early detection and intervention as well as availability of long term chronic disease management options are fueling the demand for urea cycle disorders treatment.

The Global US Urea Cycle Disorders Treatment Market is estimated to be valued at US$ 587.52 Mn  in 2024 and is expected to exhibit a CAGR of 5.3% over the forecast period 2024 to 2030.

Key Takeaways

Key players: Key players operating in the Global U.S. Urea Cycle Disorders Treatment Market are Kawasumi Laboratories Inc., Blood Purification Technologies Inc., AWAK Technologies Pte. Ltd, Triomed AB, Asahi Kasei Medical Corporation, US Kidney Research Corporation, Merit Medical Systems, NIPRO Medical Corporation, Fresenius SE & Co. KGaA.

Growing demand: Increasing uptake of newborn screening programs and emphasis on early disease management is propelling the demand for urea cycle disorders treatment products and services.

Global expansion: Leading players are exploring opportunities in international markets through partnerships and acquisitions to benefit from faster growth markets and expand their geographical footprints.

Market key trends
The government focus on implementation of newborn screening as a standard of care for all newborns is driving increased diagnosis of urea cycle disorders. Timely diagnosis through screening programs enables early therapeutic intervention leading to better long term outcomes. This emerging trend is anticipated to propel the uptake of long term treatment over the forecast period.
Porter’s Analysis
Threat of new entrants: New players to get approvals is stringent and market already has well established players. Bargaining power of buyers: Demand of treatment is inelastic and patients have very less bargaining power due to critical nature of disease. Bargaining power of suppliers: Suppliers have advantage as they supply crucial drugs and services required by patients. Threat of new substitutes: No close substitutes are available currently for treating urea cycle disorders. Competitive rivalry: Intense competition among existing players to retain market share and gain more through novel therapies and treatment options.

The geographical region where the value of U.S. urea cycle disorders treatment market is currently concentrated is North America. The region accounted for majority share owing to growing prevalence of the disease, strong healthcare infrastructure, availability of advanced treatment options and high healthcare expenditure.
Asia Pacific region is expected to be the fastest growing region for U.S. urea cycle disorders treatment market during the forecast period. This is attributed to factors such increasing healthcare spending, growing awareness about rare diseases, improving healthcare facilities and rising medical tourism in countries like India and China.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it